Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors

M.H. Langenberg, P.O. Witteveen, J. Roodhart, M.P. Lolkema, H.M.W. Verheul, M. Mergui-Roelvink, E. Brendel, J. Kratzschmar, B. Loembe, A. Nol-Boekel, O. Christensen, J.H. Schellens, E.E. Voest

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)2508-2515
JournalAnnals of Oncology
Volume22
Issue number11
DOIs
Publication statusPublished - 2011

Cite this

Langenberg, M.H. ; Witteveen, P.O. ; Roodhart, J. ; Lolkema, M.P. ; Verheul, H.M.W. ; Mergui-Roelvink, M. ; Brendel, E. ; Kratzschmar, J. ; Loembe, B. ; Nol-Boekel, A. ; Christensen, O. ; Schellens, J.H. ; Voest, E.E. / Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. In: Annals of Oncology. 2011 ; Vol. 22, No. 11. pp. 2508-2515.
@article{7bdc73d7d9af4a64afe45e6a0039fc45,
title = "Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors",
author = "M.H. Langenberg and P.O. Witteveen and J. Roodhart and M.P. Lolkema and H.M.W. Verheul and M. Mergui-Roelvink and E. Brendel and J. Kratzschmar and B. Loembe and A. Nol-Boekel and O. Christensen and J.H. Schellens and E.E. Voest",
year = "2011",
doi = "10.1093/annonc/mdq767",
language = "Undefined/Unknown",
volume = "22",
pages = "2508--2515",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "11",

}

Langenberg, MH, Witteveen, PO, Roodhart, J, Lolkema, MP, Verheul, HMW, Mergui-Roelvink, M, Brendel, E, Kratzschmar, J, Loembe, B, Nol-Boekel, A, Christensen, O, Schellens, JH & Voest, EE 2011, 'Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors' Annals of Oncology, vol. 22, no. 11, pp. 2508-2515. https://doi.org/10.1093/annonc/mdq767

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. / Langenberg, M.H.; Witteveen, P.O.; Roodhart, J.; Lolkema, M.P.; Verheul, H.M.W.; Mergui-Roelvink, M.; Brendel, E.; Kratzschmar, J.; Loembe, B.; Nol-Boekel, A.; Christensen, O.; Schellens, J.H.; Voest, E.E.

In: Annals of Oncology, Vol. 22, No. 11, 2011, p. 2508-2515.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors

AU - Langenberg, M.H.

AU - Witteveen, P.O.

AU - Roodhart, J.

AU - Lolkema, M.P.

AU - Verheul, H.M.W.

AU - Mergui-Roelvink, M.

AU - Brendel, E.

AU - Kratzschmar, J.

AU - Loembe, B.

AU - Nol-Boekel, A.

AU - Christensen, O.

AU - Schellens, J.H.

AU - Voest, E.E.

PY - 2011

Y1 - 2011

U2 - 10.1093/annonc/mdq767

DO - 10.1093/annonc/mdq767

M3 - Article

VL - 22

SP - 2508

EP - 2515

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -